查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631496

体外诊断酶市场规模、份额、趋势分析报告：按酶、疾病、技术、最终用途、地区和细分市场预测，2025-2030 年

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme (Polymerase & Transcriptase, Proteases), By Disease (Infectious Disease, Diabetes), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

体外诊断酵素市场的成长和趋势

根据 Grand View Research, Inc. 的一份新报告，全球体外诊断酶市场预计到 2030 年将达到 30.5 亿美元。预计 2025 年至 2030 年间，市场复合年增长率为 10.2%。准确、快速地诊断和治疗临床疾病对于最佳临床结果至关重要。由于其显着的生物催化特性，酶被用于多种疾病的诊断。

酵素生物感测器的发展增加了酵素在临床诊断中的效用。儘管临床诊断需要生物感测器，但其商业化程度以及从研究到临床的转化程度仍然很低。然而，随着研发力度的加大，乳酸、胆固醇和葡萄糖生物感测器正在商业化用于诊断用途。

蛋白酶是重要的讯号蛋白，对多种病理过程至关重要，包括癌症、神经疾病、发炎和心血管疾病。预计聚合酵素和转录酶在预测期内将表现出最快的复合年增长率。此外，大量提供这些酶的参与企业预计将促进增长。 Kaneka Eurogentec SA、东洋纺绩株式会社和Sekisui Diagnostics, LLC等主要企业生产和销售各种聚合酵素，包括 KOD DNA 聚合酶、Taq DNA 聚合酶、Tth DNA 聚合酶和 TTx DNA 聚合酶。

2019年，感染疾病领域占据了市场主导地位。全球新冠肺炎病例的急剧增加，推动了诊断酵素在新冠肺炎诊断上的应用率。透过即时PCR 、环介导等温扩增 PCR（LAMP-PCR）、多重 PCR 和数位 PCR 技术进行定性和定量分子检测以诊断感染疾病的可用性不断提高，推动了该领域对酵素的需求。

酵素免疫组织化学 (IHC) 因其更好的对比度和方法的兼容性而在组织学中受到青睐，这使得可以使用多种染色来检测目标成分。体外诊断（IVD）酶有多种最终用途，用于组织检体和体液的分析。体外诊断（IVD）酶被广泛的最终用户使用，包括每天进行多次分析的大型实验室和进行少量测试的小型诊所。

2019年，北美成为突出的区域市场。癌症患者数量的增加以及在切片检查样本的组织病理学测试中采用酵素是预计推动该地区市场成长的其他一些因素。庞大的目标人口、不断改善的医疗保健基础设施、大量未满足的临床需求、日益增多的政府倡议以及不断增加的先进诊断技术研发活动预计将推动亚太市场以最快的速度成长。

市场的主要企业正在致力于新产品的发布、收购、联盟、伙伴关係、地理扩张等，以加强其在市场上的地位。例如，2020 年 6 月，Codexis, Inc. 与 Alphazyme LLC 达成合作协议，生产并共同销售高保真 DNA聚合酵素、T7 RNA聚合酵素和逆转录酶。

体外诊断酵素市场报告重点

  • 以酵素计算，聚合酵素和转录酶在 2024 年占据最大份额，因为它们在分子诊断检测中已广泛应用。
  • 根据疾病，预计感染疾病部分将在整个预测期内占据市场主导地位。
  • 基于技术，组织学检测部分在 2024 年占据了最大的份额，这归因于组织学检测在癌症诊断中的效用以及各种癌症类型发病率的上升。
  • 根据最终用途，医院和诊断实验室在 2024 年占据市场主导地位。由于住院人数增加和入院癌症患者数量的增加，这些机构接收大量用于组织病理学和细胞病理学的切片检查检体。
  • 2024 年，北美占据了整个市场的主导地位，这得益于该地区大量新参与企业，包括 Innovative Research、Bio-Rad Laboratories, Inc.、Rockland Immunochemicals, Inc.、MyBioSource.com 和 RayBIoTech, Inc.

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章体外诊断酵素市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 体外诊断酵素市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析

第 4 章体外诊断酵素市场：酵素、估计与趋势分析

  • 2024 年及 2030 年酵素市场占有率
  • 细分仪表板
  • 全球体外诊断酵素市场（按酵素展望）
  • 2018-2030 年市场规模、预测及趋势分析
    • 蛋白酶
    • 聚合酵素和转录酶
    • 核糖核酸酶
    • 其他的

第五章体外诊断酵素市场：疾病预测与趋势分析

  • 2024 年及 2030 年疾病市场占有率
  • 细分仪表板
  • 全球体外诊断酶市场依疾病分类展望
  • 2018-2030 年市场规模、预测及趋势分析
    • 感染疾病
    • 糖尿病
    • 肿瘤学
    • 心臟病学
    • 肾臟科
    • 自体免疫疾病
    • 其他的

第 6 章体外诊断酵素市场：按技术、估计和趋势分析

  • 2024 年及 2030 年技术市场占有率
  • 细分仪表板
  • 全球体外诊断酶市场技术展望
  • 2018-2030 年市场规模、预测及趋势分析
    • 组织学检查
    • 分子诊断
    • 临床化学

第 7 章体外诊断酵素市场：按最终用途的估计和趋势分析

  • 2024 年及 2030 年终端用途市场占有率
  • 细分仪表板
  • 全球体外诊断酵素市场前景（依最终用途）
  • 2018-2030 年市场规模、预测及趋势分析
    • 製药和生物技术
    • 医院和诊断实验室
    • 学术实验室

第 8 章体外诊断酵素市场：区域、估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 主要市场参与企业的近期趋势及影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 2024 年主要企业的市场占有率分析
    • Merck KGaA
    • Codexis, Inc
    • F. Hoffmann-La Roche Ltd
    • Amano Enzymes Inc
    • Advanced Enzymes Technologies Ltd.
    • Biocatalysts Ltd
    • Amicogen
    • Dyadic International
    • BBI Solutions
    • Affymetrix
Product Code: GVR-4-68039-246-6

In-vitro Diagnostics Enzymes Market Growth & Trends:

The global in-vitro diagnostics enzymes market size is anticipated to reach USD 3.05 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.2% from 2025 to 2030. Accurate and rapid diagnosis and treatment of clinical disorders are essential for optimal clinical outcomes. Owing to the noteworthy biocatalytic properties, enzymes are used in the diagnosis of a wide range of diseases.

The development of enzyme biosensors has increased the enzyme utility in clinical diagnostics. Despite the necessity in clinical diagnosis, the commercialization and translation of biosensors from research to clinics are still low. However, with an increase in R&D efforts, lactate, cholesterol, and glucose biosensors have been commercialized for diagnostic use.

Proteases are important signaling proteins that are critical to a few pathological processes, including cancer, neurological, inflammatory, and cardiovascular disorders. Polymerase and transcriptase enzymes are expected to exhibit the fastest CAGR over the forecast period. In addition, the presence of a substantial number of players that offer these enzymes is expected to enhance the growth. Key players such as Kaneka Eurogentec S.A.; Toyobo Co., Ltd.; and Sekisui Diagnostics, LLC manufacture and distribute a wide range of polymerases, including KOD DNA Polymerase, Taq DNA Polymerase, Tth DNA Polymerase, and TTx DNA Polymerase.

The infectious disease segment dominated the market in 2019. An exponential rise in the COVID-19 cases globally drives the adoption rate of diagnostic enzymes for COVID-19 diagnosis. An increase in the availability of qualitative and quantitative molecular assays based on real-time PCR, Loop-mediated Isothermal Amplification- PCR (LAMP-PCR), multiplex PCR, and digital PCR technologies for the diagnosis of infectious diseases drives the demand for enzymes in this segment.

Enzymatic immunohistochemistry (IHC) is preferred for histology owing to a better contrast ratio and the method's compatibility for use with multiple stains for the detection of target components. IVD enzymes are employed in different end-use settings for the analysis of tissue specimens and bodily fluids. A wide range of end users including large laboratories that conduct multiple analyses in a day and smaller clinics that conduct a few tests use enzymes for in-vitro diagnostics (IVD).

North America emerged as a prominent regional market in 2019. A rise in the number of cancer cases and the adoption of enzymes for histopathology of biopsy samples are some of the other factors expected to propel market growth in the region. The presence of a large target population, improvements in healthcare infrastructure, high unmet clinical needs, increase in government initiatives, and rise in R&D activities for advanced diagnostic techniques are anticipated to drive the Asia Pacific market with the fastest growth rate.

The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence. For instance, in June 2020, Codexis, Inc. signed a collaboration agreement with Alphazyme LLC for the manufacture and co-marketing of high-fidelity DNA polymerase, T7 RNA polymerase, and reverse transcriptase.

In-vitro Diagnostics Enzymes Market Report Highlights:

  • By enzyme type, polymerase and transcriptase enzymes held the largest share in 2024 owing to their wide applications in molecular diagnostic assays
  • Based on disease type, the infectious disease segment is expected to dominate the market throughout the forecast period
  • In terms of technology type, the histology assays segment held the largest share in 2024 owing to the utility of histology assays in cancer diagnostics, coupled with a rising incidence of different cancer types
  • By end use, hospital and diagnostic labs dominated the market in 2024. They witness a high inflow of biopsy specimens for histopathology and cytopathology because of an increase in hospitalization and rise in the number of hospital admissions for cancer patients
  • North America dominated the overall market in 2024 owing to the presence of a substantial number of players in this region including Innovative Research; Bio-Rad Laboratories, Inc.; Rockland Immunochemicals, Inc.; MyBioSource.com; and RayBiotech, Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Enzyme
    • 1.2.2. Disease
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Enzyme outlook
    • 2.2.2. Disease outlook
    • 2.2.3. End use outlook
    • 2.2.4. Technology outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. In-vitro Diagnostics Enzymes Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Advancements in Diagnostic Technologies
      • 3.2.1.3. Rising Demand for Personalized Medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Tests
      • 3.2.2.2. Lack of Awareness in Emerging Markets
  • 3.3. In-vitro Diagnostics Enzymes Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. In-vitro Diagnostics Enzymes Market: Enzyme Estimates & Trend Analysis

  • 4.1. Enzyme Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global In-vitro Diagnostics Enzymes Market by Enzyme Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Proteases
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Polymerase & Transcriptase
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Ribonuclease
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In-vitro Diagnostics Enzymes Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global In-vitro Diagnostics Enzymes Market by Disease Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Infectious Disease
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 5.4.1.2. COVID -19 Testing
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Hepatitis
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. HIV
        • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
        • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Diabetes
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Oncology
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Cardiology
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Nephrology
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Autoimmune Diseases
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Others
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In-vitro Diagnostics Enzymes Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global In-vitro Diagnostics Enzymes Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Histology Assays
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Molecular Diagnostics
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. PCR Assays
        • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. NGS Assays
        • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Others
        • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Clinical Chemistry
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In-vitro Diagnostics Enzymes Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global In-vitro Diagnostics Enzymes Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Pharma & Biotech
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Hospital & Diagnostic Labs
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Academic Labs
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. In-vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Target disease prevalence
      • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Target disease prevalence
      • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Target disease prevalence
      • 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Target disease prevalence
      • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Target disease prevalence
      • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Target disease prevalence
      • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Target disease prevalence
      • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Target disease prevalence
      • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Target disease prevalence
      • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Target disease prevalence
      • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Target disease prevalence
      • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Target disease prevalence
      • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Target disease prevalence
      • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Target disease prevalence
      • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Target disease prevalence
      • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Target disease prevalence
      • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Target disease prevalence
      • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Target disease prevalence
      • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
      • 8.8.1.6. )
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Target disease prevalence
      • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. Target disease prevalence
      • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Target disease prevalence
      • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Target disease prevalence
      • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Target disease prevalence
      • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Merck KGaA
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Codexis, Inc
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. F. Hoffmann-La Roche Ltd
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Amano Enzymes Inc
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Advanced Enzymes Technologies Ltd.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Biocatalysts Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Amicogen
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Dyadic International
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. BBI Solutions
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Affymetrix
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 3 North America in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 7 U.S. in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 8 U.S. in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 9 U.S. in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 10 U.S. in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 12 Canada in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Canada in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Canada in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 16 Mexico in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 17 Mexico in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 18 Mexico in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 20 Europe in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 21 Europe in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Europe in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 24 Germany in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 25 Germany in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 26 Germany in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Germany in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 29 UK in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 30 UK in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 31 UK in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 33 France in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 34 France in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 35 France in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 37 Italy in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 38 Italy in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 39 Italy in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 41 Spain in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 42 Spain in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Spain in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Sweden in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 45 Sweden in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 46 Sweden in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Sweden in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Norway in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 49 Norway in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 50 Norway in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 51 Norway in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Denmark in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 53 Denmark in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Denmark in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Denmark in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 61 China in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 62 China in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 63 China in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 64 China in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 66 Japan in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 67 Japan in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 68 Japan in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 70 India in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 71 India in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 72 India in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Australia in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 74 Australia in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 75 Australia in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 76 Australia in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Thailand in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 78 Thailand in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 79 Thailand in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 80 Thailand in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 81 South Korea in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 82 South Korea in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 83 South Korea in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 84 South Korea in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 86 Latin America in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 87 Latin America in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 88 Latin America in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Latin America in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 90 Brazil in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 91 Brazil in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 92 Brazil in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 93 Brazil in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 95 Argentina in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 96 Argentina in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 97 Argentina in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 98 Middle East and Africa in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 103 South Africa in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 104 South Africa in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 105 South Africa in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 106 South Africa in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 112 UAE in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 113 UAE in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 114 UAE in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 116 Kuwait in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 117 Kuwait in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 118 Kuwait in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 In-vitro diagnostics enzymes: Market outlook
  • Fig. 9 In-vitro diagnostics enzymes: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 In-vitro diagnostics enzymes market driver impact
  • Fig. 15 In-vitro diagnostics enzymes market restraint impact
  • Fig. 16 In-vitro diagnostics enzymes market strategic initiatives analysis
  • Fig. 17 In-vitro diagnostics enzymes market: Enzyme movement analysis
  • Fig. 18 In-vitro diagnostics enzymes market: Enzyme outlook and key takeaways
  • Fig. 19 Proteases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Polymerase & transcriptase market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Ribonuclease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 In-vitro diagnostics enzymes market: Disease type movement analysis
  • Fig. 24 In-vitro diagnostics enzymes market: Disease type outlook and key takeaways
  • Fig. 25 Infectious disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiology market estimates and forecasts, 2018 - 2030
  • Fig. 29 Nephrology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Autoimmune diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 In-vitro diagnostics enzymes market: Technology movement analysis
  • Fig. 33 In-vitro diagnostics enzymes market: Technology outlook and key takeaways
  • Fig. 34 Histology assays market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Clinical chemistry market estimates and forecasts, 2018 - 2030
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030
  • Fig. 38 In-vitro diagnostics enzymes market: End use movement analysis
  • Fig. 39 In-vitro diagnostics enzymes market: End use outlook and key takeaways
  • Fig. 40 Pharma & biotech market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Hospital & diagnostic labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Contract Research Organizations (CROs) market estimates and forecasts, 2018 - 2030
  • Fig. 43 Academic labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Global in-vitro diagnostics enzymes market: Regional movement analysis
  • Fig. 45 Global in-vitro diagnostics enzymes market: Regional outlook and key takeaways
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)